Stem Cell Therapeutics Corp. Announces Positive Review By Data Safety And Monitoring Board For The Phase IIb Stroke …
Stem Cell Therapeutics Corp. (”SCT” or the “Company”) (TSX VENTURE:SSS) announced today it has been advised by the Data Safety Monitoring Board (”DSMB”) that a regularly scheduled safety analysis has been completed and the DSMB has recommended the Phase IIb stroke trial to continue as per the protocol.
[Read the full article here]Related News:
Stem Cell Therapeutics Corp. Announces the Third and Final Positive Review by the Data Safety and Monitoring Board for …
Stem Cell Therapeutics Corp. Announces Second Positive Review by Data Safety and Monitoring Board for the Modified …
Stem Cell Therapeutics Corp. Announces Positive Review By Data Safety And Monitoring Board For The Phase IIb Stroke Trial